Ying Su

Ying Su

Sanford-Burnham Medical Research Institute, USA

Title: Structure-based discovery of new modulators targeting nuclear X receptor alpha for cancer therapy


Ying Su, PhD, is computational chemist with over 15 years of experience on computer-aided drug design. Shereceived her PhD from the University of California, San Diego. After a postdoctoral appointment at the Scripps Research Institute, she worked for several local biotech companies.She joined the Sanford-Burnham Medical Research Institute in 2005 to build and lead a HTS informatics and Cheminformticsgroup. She is co-author of over 40 peer-reviewed scientific publications.


Retinoid X receptor-alpha (RXR) is implicated in the regulation of many biological processes and also represents a unique intracellular target for pharmacologic interventions.Efforts on discovery of small molecules targeting RXR have been primarily focused on the molecules that bind to its classical ligand-binding pocket (LBP). Using structure-based approach and in collaboration with a multi-disciplinary team, we have identified novel RXR modulators that use new binding mechanisms to mediate the biological functions of RXR. The new compounds can effectively suppress AKT activation and promotes apoptosis of cancer cells in a RXR-dependent mannerby inhibitingthe interaction between a truncated RXR and the p85 subunit of PI3K.